NCT01015014View on ClinicalTrials.gov

Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 5, 2009

Primary Completion Date

May 13, 2010

Study Completion Date

May 13, 2010

Conditions
Gram-negative Bacterial Infection
Interventions
DRUG

AN3365

LP, 600 mg vial; reconstituted in Normal Saline

DRUG

Placebo

0.9% sodium chloride for injection

Trial Locations (1)

Unknown

CMAX, Adelaide

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY